<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34469007</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>11</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>11</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1365-2885</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>45</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of veterinary pharmacology and therapeutics</Title>
          <ISOAbbreviation>J Vet Pharmacol Ther</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Plasma and urine pharmacokinetics of hydroxyzine and cetirizine following repeated oral administrations to exercised horses.</ArticleTitle>
        <Pagination>
          <StartPage>46</StartPage>
          <EndPage>53</EndPage>
          <MedlinePgn>46-53</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/jvp.13010</ELocationID>
        <Abstract>
          <AbstractText>Hydroxyzine and cetirizine are first- and second-generation oral antihistamine drugs, respectively, used to treat allergic reactions in horses. Cetirizine is also a metabolite of hydroxyzine, which may lead to complexities in regulating their use in equine sporting events. The aim of the research was to be able to provide detection times (DT) from pharmacokinetic studies in thoroughbred horses to better inform trainers, and their veterinary surgeons, prescribing these substances for treatment of Thoroughbred racehorses. Six and two horses were given 9 repeated administrations of hydroxyzine HCl (500 mg BID) or cetirizine HCl (190 mg BID), respectively. Plasma and urine hydroxyzine and cetirizine concentrations were measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS). A holistic non-linear mixed effects PK model was developed that described both plasma and urine concentrations of hydroxyzine and cetirizine, either from administration of each individually or cetirizine as a metabolite of hydroxyzine. Using the parameters obtained from this PK model in conjunction with methodology developed by Toutain afforded possible screening limits (SL) that can regulate for a DT of 4 days in either plasma or urine. Hydroxyzine and cetirizine concentration prediction intervals for the 80<sup>th</sup> , 95<sup>th</sup> and 99<sup>th</sup> percentiles of a virtual horse population were performed in order to assess the statistical protection of the DT. However, it is down to the individual racing authorities to apply their own risk management.</AbstractText>
          <CopyrightInformation>© 2021 John Wiley &amp; Sons Ltd.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Paine</LastName>
            <ForeName>Stuart W</ForeName>
            <Initials>SW</Initials>
            <Identifier Source="ORCID">0000-0001-9443-2311</Identifier>
            <AffiliationInfo>
              <Affiliation>School of Veterinary Medicine and Science, University of Nottingham, Nottingham, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Aldurdunji</LastName>
            <ForeName>Mohammed</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>School of Veterinary Medicine and Science, University of Nottingham, Nottingham, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Garth-Greeves</LastName>
            <ForeName>Alix</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>LGC Ltd Fordham, Fordham, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Muir</LastName>
            <ForeName>Tessa</ForeName>
            <Initials>T</Initials>
            <Identifier Source="ORCID">0000-0002-8056-1160</Identifier>
            <AffiliationInfo>
              <Affiliation>British Horse Racing Authority, London, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hincks</LastName>
            <ForeName>Pamela R</ForeName>
            <Initials>PR</Initials>
            <Identifier Source="ORCID">0000-0002-0810-9284</Identifier>
            <AffiliationInfo>
              <Affiliation>LGC Ltd Fordham, Fordham, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>09</Month>
          <Day>01</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>J Vet Pharmacol Ther</MedlineTA>
        <NlmUniqueID>7910920</NlmUniqueID>
        <ISSNLinking>0140-7783</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006634">Histamine H1 Antagonists</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004364">Pharmaceutical Preparations</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>30S50YM8OG</RegistryNumber>
          <NameOfSubstance UI="D006919">Hydroxyzine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>YO7261ME24</RegistryNumber>
          <NameOfSubstance UI="D017332">Cetirizine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017332" MajorTopicYN="N">Cetirizine</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002853" MajorTopicYN="N">Chromatography, Liquid</DescriptorName>
          <QualifierName UI="Q000662" MajorTopicYN="N">veterinary</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006634" MajorTopicYN="N">Histamine H1 Antagonists</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006736" MajorTopicYN="N">Horses</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006919" MajorTopicYN="Y">Hydroxyzine</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004364" MajorTopicYN="Y">Pharmaceutical Preparations</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053719" MajorTopicYN="N">Tandem Mass Spectrometry</DescriptorName>
          <QualifierName UI="Q000662" MajorTopicYN="N">veterinary</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">cetirizine</Keyword>
        <Keyword MajorTopicYN="N">detection time</Keyword>
        <Keyword MajorTopicYN="N">horse</Keyword>
        <Keyword MajorTopicYN="N">hydroxyzine</Keyword>
        <Keyword MajorTopicYN="N">population pharmacokinetics</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>1</Day>
          <Hour>12</Hour>
          <Minute>42</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34469007</ArticleId>
        <ArticleId IdType="doi">10.1111/jvp.13010</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>REFERENCES</Title>
        <Reference>
          <Citation>Knych, H. K., Stanley, S. D., Arthur, R. M., &amp; McKemie, D. S. (2016). Elimination of cetirizine following administration of multiple doses to exercised Thoroughbred horses. Journal of Veterinary Pharmacology and Therapeutics, 39(5), 522-524. https://doi.org/10.1111/jvp.12318</Citation>
        </Reference>
        <Reference>
          <Citation>Knych, H. K., Weiner, D., Steinmetz, S., Flynn, K., &amp; McKemie, D. S. (2019). Pharmacokinetics of hydroxyzine and cetirizine following oral administration of hydroxyzine to exercised Thoroughbred horses. Journal of Veterinary Pharmacology and Therapeutics, 42(6), 617-623. https://doi.org/10.1111/jvp.12808</Citation>
        </Reference>
        <Reference>
          <Citation>Olsén, L., Bondesson, U., Broström, H., Tjälve, H., &amp; Ingvast-Larsson, C. (2008). Cetirizine in horses: Pharmacokinetics and pharmacodynamics following repeated oral administration. The Veterinary Journal, 177, 242-249. https://doi.org/10.1016/j.tvjl.2007.03.026</Citation>
        </Reference>
        <Reference>
          <Citation>Simons, F., &amp; Simons, K. (2011). Histamine and H1-antihistamines: Celebrating a century of progress. The Journal of Allergy and Clinical Immunology, 128(6), 1139-1150. https://doi.org/10.1016/j.jaci.2011.09.005</Citation>
        </Reference>
        <Reference>
          <Citation>Toutain, P. L., &amp; Lassourd, V. (2002). Pharmacokinetic/pharmacodynamic approach to assess irrelevant plasma or urine drug concentrations in postcompetition samples for drug control in the horse. Equine Veterinary Journal, 34, 242-249. https://doi.org/10.2746/042516402776185985</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
